Clinical trials: Adaptive Radiotherapy
Cancer, Endometrial Cancer
Adaptive Radiotherapy for Safe Hypofractionation
This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2)…
- Conditions
- Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer
- Trial name
- ART-Hypo (NCT07516210)
- Testing
- Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
NSCLC (Advanced Non-small Cell Lung Cancer), Adaptive Radiotherapy
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
Locally advanced non-small cell lung cancer (LA-NSCLC) patients could benefit in overall and progression-free survival from regular dosimetric treatment plan adaptations during radiotherapy.
- Trial name
- ECLAIR (NCT07259447)
- Testing
- CBCT-based adaptive radiotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bladder Cancer
Evaluation of Ultrasound Probe for Use in Bladder Radiotherapy
Muscle-invasive bladder cancer affects over 3,000 new patients in the UK each year and radiotherapy comprises a key part of the treatment pathway for many of them.
- Trial name
- NCT01698359
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Glioma
Image Guided Therapy in the Treatment of Gliomas
RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor definition, thus may lead to better tumor targeting and avoid damaging critical parts of normal brain.
- Trial name
- NCT01263821
- Testing
- Diffusion-weighted magnetic resonance imaging, Perfusion-weighted magnetic resonance imaging, Functional magnetic resonance imaging
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Combination Therapy for the Treatment of Diffuse Midline Gliomas
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- PNOC022 (NCT05009992)
- Testing
- ONC201, Radiation Therapy, Paxalisib
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 360 people
- Sponsor
- University of California, San Francisco
Prostate Cancer Metastatic Castration-Resistant
External Beam and Radioligand Radiotherapy for mCRPC
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer.
- Trial name
- ARREST (NCT07354594)
- Testing
- External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Oropharyngeal Carcinoma
Off-line Adaptive Proton Therapy
This prospective in-silico study evaluates a novel Off-line Adaptive Proton Therapy (o-APT) workflow for patients with oropharyngeal cancer receiving proton therapy.
- Trial name
- o-APT (NCT07866547)
- Testing
- Off-line Adaptive Proton Therapy (o-APT) Workflow Evaluation
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Bladder Cancer
Study of Tumour Focused Radiotherapy for Bladder Cancer
Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the bladder (muscle invasive) and is life…
- Trial name
- RAIDER (NCT02447549)
- Testing
- WBRT, SART, DART
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 345 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Skin Cancer
EUREKA: Evaluating Ultraviolet Radiation Exposure in Kids for Adaptive Intervention
This project will pilot a Just In Time Adaptive Intervention (JITAI) approach to providing feedback on child UVR exposure to children and their parents, with the ultimate goal of improving child use of sun protection strategies…
- Trial name
- EUREKA (NCT07204704)
- Testing
- EUREKA Intervention
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Utah
Fibrosis Syndrome, Lymphedema
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer.
- Conditions
- Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer, Fibrosis
- Trial name
- NCT06912763
- Testing
- Pravastatin (drug), Pentoxifylline, ketoprofen
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- M.D. Anderson Cancer Center